GleamWall
中文EN

BMRA BIOMERICA INC

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 73290 · Fiscal year ends 05/31

Financial factors as of 2026-08-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-11.2%
TTM net income YoY-37.0%
TTM EPS YoY-9.2%
Revenue 3-yr CAGR-7.1%
Net income 3-yr CAGR—

Margins

Gross margin0.9%
Operating margin-125.2%
Net margin-115.5%
FCF margin—
EBITDA margin-123.6%

Returns

ROE-113.8%
ROA-67.1%
ROIC (approx.)-284.4%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets54.8%
Debt / equity0.00x
Current ratio1.91x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.79x
Accruals ratio-14.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-05-31FY20252025-05-31
Income statement
Revenue$4.45M$5.31M
Cost of revenue$4.09M$4.81M
Gross profit$362,000$498,000
R&D expense$788,000$1.02M
SG&A expense$4.89M$4.61M
Operating income-$5.32M-$5.14M
Pretax income-$3.75M-$4.97M
Income tax$23,000$1,000
Net income-$3.77M-$4.97M
EBITDA-$5.24M-$5.05M
EPS (basic)-1.30-2.16
EPS (diluted)-1.30-2.16
Weighted avg. shares (diluted)2.91M2.30M
Balance sheet
Cash & equivalents$1.31M$2.40M
Receivables$785,000$731,000
Inventory$1.71M$1.49M
Current assets$4.02M$4.88M
PP&E, net$78,000$135,000
Intangibles$209,000$228,000
Total assets$6.76M$5.95M
Current liabilities$2.48M$1.74M
Total liabilities$4.13M$1.84M
Shareholders' equity$2.63M$4.11M
Shares outstanding3.20M2.55M
Cash flow statement
Operating cash flow-$3.42M-$3.84M
Investing cash flow-$1,000-$37,000
Financing cash flow$2.33M$2.11M
Depreciation & amortization$77,000$87,000
Stock-based compensation$476,000$460,000

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.